Avalyn Pharma Inc. (AVLN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Avalyn Pharma Inc. (AVLN) closed at USD 23.69 on 2026-10-14, a change of -19.7 % over the past year, with a market capitalization of USD 1.09B.

Avalyn Pharma Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Avalyn Pharma Inc. key figures

Previous close

USD 23.69 (2026-10-14)

1-year change

-19.7 %

Market cap

USD 1.09B

Enterprise value

USD 757.05M

P/E ratio (trailing)

-9.66

P/E ratio (forward)

-12.97

EPS (trailing)

-2.55

EPS (forward)

-1.90

PEG ratio

n/a

Price to book

2.74

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.45

Employees

55

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Avalyn Pharma Inc.

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Avalyn Pharma Inc. and compare it with other stocks.